MORRISVILLE, N.C.--(BUSINESS WIRE)--Circassia Pharmaceuticals Inc. (āCircassiaā or āthe Companyā), today announced that the US Food and Drug Administration has approved DUAKLIR® PRESSAIR® (aclidinium ...
Oxford, UK - 7 September 2017: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces positive ...
Each actuation provides a metered dose of 12mg of the formulation which contains lactose monohydrate as the carrier, 400mcg of aclidinium bromide, and 12mcg of formoterol fumarate. Duaklir Pressair ...
AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a ...
MISSISSAUGA, ON, Oct. 29, 2015 /CNW/ - AstraZeneca Canada announced today that DUAKLIR ā¢ GENUAIR ® (aclidinium bromide/formoterol fumarate dihydrate 400/12 Ī¼g) is now available in Canada for the ...
Oxford, UK and Morrisville, NC, United States - 21 October 2019: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty pharmaceutical company focused on respiratory ...
Circassia announced that the Food and Drug Administration (FDA) has approved Duaklir Pressair (aclidinium bromide, formoterol fumarate) for the maintenance treatment of COPD. Circassia announced that ...
Oxford, UK - 1 April 2019: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and ...
AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results